An organizational readiness intervention and randomized controlled trial to test strategies for implementing substance use disorder treatment into primary care: SUMMIT study protocol

Implementation Science

Volumn 10, Issue 1, 2015, Pages

  Ober, Allison J ^a   Watkins, Katherine E ^a   Hunter, Sarah B ^a   Lamp, Karen ^b   Lind, Mimi ^b   Setodji, Claude M ^a  

^a RAND CORPORATION   (United States)

^b Venice Family Clinic   (United States)

Author keywords

Care coordination; Collaborative care; Evidence based substance use disorder treatment; Extended release injectable naltrexone; Implementation; Medication assisted treatment; Organizational readiness; Primary care; Suboxone; Vivitrol; Buprenorphine naloxone; Motivational interviewing

Indexed keywords

CONTROLLED STUDY; DECISION SUPPORT SYSTEM; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HUMAN; LEADERSHIP; MENTAL HEALTH; METHODOLOGY; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PATIENT CARE; PATIENT SATISFACTION; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIAL; SUBSTANCE-RELATED DISORDERS;

DECISION SUPPORT TECHNIQUES; EVIDENCE-BASED MEDICINE; HEALTH SERVICES ACCESSIBILITY; HUMANS; LEADERSHIP; MENTAL HEALTH; ORGANIZATIONAL INNOVATION; PATIENT SATISFACTION; PATIENT-CENTERED CARE; PRIMARY HEALTH CARE; RESEARCH DESIGN; SUBSTANCE-RELATED DISORDERS;

EID: 84929334020     PISSN: None     EISSN: 17485908     Source Type: Journal    
DOI: 10.1186/s13012-015-0256-7     Document Type: Article

References (80)

1. U.S. Department of Health and Human Services. Results from the 2013 national survey on drug use and health: summary of national findings, NSDUH Series H-46, HHS Publication No. (SMA) 14-4863. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014.
2. Yoon YH, Yi HY. Surveillance report #93: liver cirrhosis mortality in the United States, 1970-2009. National Institute on Alcohol Abuse and Alcoholism: Bethesda, MD; 2012.
3. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238-45. doi:10.1001/jama.291.10.1238.
4. National Drug Intelligence Center. The economic impact of illicit drug use on American society. Washington D.C: United States Department of Justice; 2011.
5. Centers for Disease Control and Prevention. Excessive drinking costs U.S. $223.5 billion. In: CDC features. Atlanta: National Center for Chronic Disease Prevention and Health Promotion, Division of Adult and Community Health; 2014. http://www.cdc.gov/features/alcoholconsumption/. Accessed June 12 2014.
6. Bouchery EE, Harwood HJ, Sacks JJ, Simon CJ, Brewer RD. Economic costs of excessive alcohol consumption in the U.S., 2006. Am J Prev Med. 2011;41(5):516-24.
7. U.S. Department of Health and Human Services. Results from the 2012 national survey on drug use and health: summary of national findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
8. Pilowsky DJ, Wu LT. Screening for alcohol and drug use disorders among adults in primary care: a review. Subst Abuse Rehabil. 2012;3(1):25-34. doi:10.2147/SAR.S30057.
9. Cherpitel CJ, Ye Y. Trends in alcohol- and drug-related emergency department and primary care visits: data from four U.S. national surveys (1995-2010). J Stud Alcohol Drugs. 2012;73(3):454-8.
10. Blackwell D, Lucas J, Clarke T. Summary health statistics for U.S. adults: national health interview survey, 2012. In: Vital Health Stat National Center for Health Statistics, editor. 2014
11. Parthasarathy S, Mertens J, Moore C, Weisner C. Utilization and cost impact of integrating substance abuse treatment and primary care. Med Care. 2003;41(3):357-67.
12. Drainoni ML, Farrell C, Sorensen-Alawad A, Palmisano JN, Chaisson C, Walley AY. Patient perspectives of an integrated program of medical care and substance use treatment. Aids Patient Care STDS. 2014;28(2):71-81. doi:10.1089/apc.2013.0179.
13. U.S. Department of Health and Human Services. Treatment Improvement Protocol (TIP) 49: incorporating alcohol pharmacotherapies into medical practice, HHS Publication No SMA13-4380. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2009.
14. U.S. Department of Health and Human Services. Technical Assistance Publication (TAP) 30: buprenorphine: a guide for nurses, HHS Publication No SMA09-4376. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2009.
15. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949-58. doi:10.1056/NEJMoa022164.
16. O'Malley SS, Froehlich JC. Advances in the use of naltrexone: an integration of preclinical and clinical findings. Recent Dev Alcohol. 2003;16:217-45.
17. Substance Abuse and Mental Health Services Administration. Motivational enhancement therapy. In: SAMSHA's National Registry of Evidence-Based Programs and Practices. 2007. http://www.nrepp.samhsa.gov/ViewIntervention.aspx?id=347. Accessed September 14 2011.
18. Ball SA, Martino S, Nich C, Frankforter TL, Van Horn D, Crits-Christoph P, et al. Site matters: multisite randomized trial of motivational enhancement therapy in community drug abuse clinics. J Consult Clin Psychol. 2007;75(4):556-67. doi:10.1037/0022-006X.75.4.556.
19. Miller WR, Benefield RG, Tonigan JS. Enhancing motivation for change in problem drinking: a controlled comparison of two therapist styles. J Consult Clin Psychol. 1993;61(3):455-61.
20. Boldt R. Obstacles to the development and use of pharmacotherapies for addiction. J Health Care Law Pol. 2010;13:1-6.
21. Buck JA. The looming expansion and transformation of public substance abuse treatment under the affordable care act. Health Aff (Millwood). 2011;30(8):1402-10. doi:10.1377/hlthaff.2011.0480.
22. Aspy C, Mold J, Thompson D, Blondel R, Lander P, Reilly K, et al. Integrating screening and interventions for unhealthy behaviors into primary care practices. Am J Prev Med. 2008;35(Suppl):S373-80.
23. Bradley KA, Williams EC, Achtmeyer CE, Volpp B, Collins BJ, Kivlahan DR. Implementation of evidence-based alcohol screening in the Veterans Health Administration. Am J Manag Care. 2006;12(10):597-606.
24. Friedmann P, McCullough D, Chin M, Saitz R. Screening and intervention for alcohol problems: a national survey of primary care physicians and psychiatrists. J Gen Intern Med. 2000;15:84-91.
25. Urada D, Teruya C, Gelberg L, Rawson R. Integration of substance use disorder services with primary care: health center surveys and qualitative interviews. Subst Abuse Treat Prev Policy. 2014;9:15. doi:10.1186/1747-597X-9-15.
26. Quest TL, Merrill JO, Roll J, Saxon AJ, Rosenblatt RA. Buprenorphine therapy for opioid addiction in rural Washington: the experience of the early adopters. J Opioid Manag. 2012;8(1):29-38.
27. Gueorguieva R, Wu R, Donovan D, Rounsaville BJ, Couper D, Krystal JH, et al. Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study. Drug Alcohol Depend. 2009;107(2-3):221-9. doi:10.1016/j.drugalcdep.2009.10.017.
28. West SL, Garbutt JC, Carey TS, Lux LJ, Jackman AM, Tolleson-Rinehart S, et al. Pharmacotherapy for alcohol dependence. Evid Rep Technol Assess (Summ). 1999;3:1-5.
29. Fixsen DL, Naoom SF, Blase KA, Friedman RM, Wallace F. Implementation research: a synthesis of the literature. University of South Florida, Louis de la Parte Florida Mental Health Institute, The National Implementation Research Network (FMHI Publication #231); 2005.
30. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50. doi:10.1186/1748-5908-4-50.
31. Powell BJ, McMillen JC, Proctor EK, Carpenter CR, Griffey RT, Bunger AC, et al. A compilation of strategies for implementing clinical innovations in health and mental health. Med Care Res Rev. 2011;69(2):123-57. doi:10.1177/1077558711430690.
32. Weiner BJ, Amick H, Lee SY. Conceptualization and measurement of organizational readiness for change: a review of the literature in health services research and other fields. Med Care Res Rev. 2008;65(4):379-436. doi:10.1177/1077558708317802.
33. Weiner BJ, Lewis MA, Linnan LA. Using organization theory to understand the determinants of effective implementation of worksite health promotion programs. Health Educ Res. 2009;24(2):292-305. doi:10.1093/her/cyn019.
34. Wagner EH, Glasgow RE, Davis C, Bonomi AE, Provost L, McCulloch D, et al. Quality improvement in chronic illness care: a collaborative approach. Jt Comm J Qual Improv. 2001;27(2):63-80.
35. Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving chronic illness care: translating evidence into action. Health Aff (Millwood). 2001;20(6):64-78.
36. Unutzer J, Katon W, Callahan CM, Williams Jr JW, Hunkeler E, Harpole L, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA. 2002;288(22):2836-45.
37. Katon W, Unutzer J, Wells EA, Jones L. Collaborative depression care: history, evolution and ways to enhance dissemination and sustainability. Gen Hosp Psychiatry. 2010;32:456-64.
38. Unutzer J, Katon WJ, Fan MY, Schoenbaum MC, Lin EH, Della Penna RD, et al. Long-term cost effects of collaborative care for late-life depression. Am J Manag Care. 2008;14(2):95-100.
39. McGregor M, Lin EH, Katon WJ. TEAMcare: an integrated multicondition collaborative care program for chronic illnesses and depression. J Ambul Care Manage. 2011;34(2):152-62. doi:10.1097/JAC.0b013e31820ef6a4.
40. Katon WJ. Collaborative care: evidence-based models that improve primary care depressive outcomes. CNS Spectr. 2009;14(12 Suppl 14):10-3.
41. Ell K, Katon W, Xie B, Lee PJ, Kapetanovic S, Guterman J, et al. One-year postcollaborative depression care trial outcomes among predominantly Hispanic diabetes safety net patients. Gen Hosp Psychiatry. 2011;33(5):436-42. doi:10.1016/j.genhosppsych.2011.05.018.
42. Katon W, Guico-Pabia CJ. Improving quality of depression care using organized systems of care: a review of the literature. Prim Care Companion CNS Disord. 2011;13(1). doi:10.4088/PCC.10r01019blu.
43. Blasinsky M, Goldman HH, Unutzer J. Project IMPACT: a report on barriers and facilitators to sustainability. Adm Policy Ment Health. 2006;33(6):718-29. doi:10.1007/s10488-006-0086-7.
44. Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med. 2012;27(6):669-76. doi:10.1007/s11606-011-1962-8.
45. Myles J, FL, Raybould T. A double-blind randomised controlled trial of buprenorphine/naloxone (suboxone) versus methadone/lofexidine for the detoxification of opiate-dependent addicts. Drug Alcohol Depend. 2000;60 Suppl 1:S156.
46. Tofighi B, Grossman E, Williams AR, Biary R, Rotrosen J, Lee JD. Outcomes among buprenorphine-naloxone primary care patients after Hurricane Sandy. Addict Sci Clin Pract. 2014;9:3. doi:10.1186/1940-0640-9-3.
47. Mauger S, Fraser R, Gill K. Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence. Neuropsychiatr Dis Treat. 2014;10:587-98. doi:10.2147/NDT.S39692.
48. Doolittle B, Becker W. A case series of buprenorphine/naloxone treatment in a primary care practice. Subst Abus. 2011;32(4):262-5. doi:10.1080/08897077.2011.599256.
49. Balhara YP. Time to include buprenorphine-naloxone combination in the WHO model list of essential medicines. J Opioid Manag. 2014;9(4):237.
50. Lee JD, Grossman E, Huben L, Manseau M, McNeely J, Rotrosen J, et al. Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months. J Subst Abuse Treat. 2012;43(4):458-62.
51. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617-25.
52. Kranzler H, Wesson D, Billot L. Drug abuse sciences: naltrexone depot study group. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004;28:1051-9.
53. Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;108(9):1628-37.
54. Hartung DM, McCarty D, Fu R, Wiest K, Chalk M, Gastfriend DR. Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies. J Subst Abuse Treat. 2014;47(2):113-21.
55. Miller WR, Sanchez VC. Motivation of young adults for treatment and lifestyle change. In: Howard G, editor. Issues in alcohol use and misuse by young adults. Notre Dame, IN: University of Notre Dame Press; 1994. p. 55-82.
56. Miller WR, Zweben A, DiClemente CC, Rychtarik RG. Motivational enhancement therapy: a clinical research guide for therapists treating individuals with alcohol abuse and dependence. Rockville, MD: National Institutes of Health; 1994. Report No.: NIH Publication No. 94-3723.
57. U.S. Department of Health and Human Services Health Resources and Services Administration. The Affordable Care Act and Health Centers. 2013. http://bphc.hrsa.gov/about/healthcenterfactsheet.pdf. Accessed January 22 2015.
58. Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2011;38(2):65-76. doi:10.1007/s10488-010-0319-7.
59. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012;50(3):217-26. doi:10.1097/MLR.0b013e3182408812.
60. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. Arch Intern Med. 2010;170(13):1155-60.
61. WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction. 2002;97(9):1183-94.
62. Rodgers R, Hunter J, Rogers D. Influence of top management commitment on management program success. J Appl Psychol. 1993;78:151-5.
63. Kraft JM, Mezoff JS, Sogolow ED, Neumann MS, Thomas PA. A technology transfer model for effective HIV/AIDS interventions: science and practice. AIDS Educ Prev. 2000;12(5 Suppl):7-20.
64. Beidas R, Kendall P. Training therapists in evidence-based practice: a critical review of studies from a systems-contextual perspective. Clin Psychol. 2010;17:1-30.
65. Hunter S, Chinman M, Ebener P, Imm P, Wandersman A, Ryan G. Technical assistance as a prevention capacity-building tool: a demonstration using the getting to outcomes framework. Health Educ Behav. 2009;36:810-28.
66. Deming W. Out of the crisis, 1986. Cambridge, MA: Massachusetts Institute of Technology Center for Advanced Engineering Study iii; 1991.
67. Berwick DM. Developing and testing changes in delivery of care. Ann Intern Med. 1998;128(8):651-6.
68. Moore G, Benbasat I. Development of an instrument to measure the perceptions of adopting an information technology innovation. Inform Syst Res. 1991;2(3):192-222.
69. Rogers E. Diffusion of innovations. 4th ed. New York: The Free Press; 1995.
70. The National Center on Addiction and Substance Abuse (CASA). Missed opportunity: survey of primary care providers and patients on substance abuse. Columbia University; 2000.
71. Chappel JN, Veach TL, Krug RS. The substance abuse attitude survey: an instrument for measuring attitudes. J Stud Alcohol Drugs. 1985;46(1):48-52.
72. Aarons GA. Mental health provider attitudes toward adoption of evidence-based practice: the evidence-based practice attitude scale (EBPAS). Ment Health Serv Res. 2004;6(2):61-74.
73. Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid RJ, Greene SM. Development and validation of the patient assessment of chronic illness care (PACIC). Med Care. 2005;43(5):436-44.
74. Bonomi AE, Wagner EH, Glasgow RE, VonKorff M. Assessment of chronic illness care (ACIC): a practical tool to measure quality improvement. Health Serv Res. 2002;37(3):791-820. doi:10.1111/1475-6773.00049.
75. Sobell LC, Maisto SA, Sobell MB, Cooper AM. Reliability of alcohol abusers' self-reports of drinking behavior. Behav Res Ther. 1979;17:157-60.
76. Gillespie W, Holt JL, Blackwell RL. Measuring outcomes of alcohol, marijuana, and cocaine use among college students: a preliminary test of the shortened inventory of problems-alcohol and drugs (SIP-AD). J Drug Issues. 2007;37:549-68.
77. Ware Jr J, Kosinski M, Turner-Bowker D, Gandek B. How to score version 2 of the SF-12® health survey (with a supplement documenting version 1). Lincoln, RI: Quality Metric Incorporated; 2002.
78. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-13.
79. Spitzer R, Kroenke K, Williams J, Lowe B. A brief measure for assessing generalized anxiety disorder. Arch Inern Med. 2006;166:1092-7.
80. Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. Eval Program Plann. 1979;2(3):197-207.